Laboratory Study of Early Tumor Markers in the Peripheral Blood of Glioblastoma Multiforme Patients
| Status: | Completed |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 89 |
| Updated: | 5/27/2013 |
| Start Date: | October 2009 |
| End Date: | August 2013 |
| Contact: | Jennifer West, BSN |
| Email: | jennifer.west@neurosurgery.ufl.edu |
| Phone: | 352-273-7981 |
Human Glioblastoma Multiforme (GBM) Circulating Tumor Cells (CTCs) as Early, Less Invasive Markers of Progression and Response
The purpose of this study is to determine if tumor cells can be detected in the blood of
patients diagnosed with a brain tumor.
Despite aggressive therapies, Glioblastoma Multiforme (GBM) is rapidly fatal. GBMs are
increasingly recognized for occasionally metastasizing through the peripheral blood to
distant locations. This research study involves the detection and novel characterization of
human GBM (hGBM) circulating tumor cells (CTCs) within the peripheral blood of brain tumor
patients by identifying their unique cell surface antigen profile, determining an optimal
isolation protocol, and quantitatively and qualitatively reporting the yield and
characteristics.
Inclusion Criteria:
- 18 to 89 years of age
- Weight of at least 110 pounds
- Able to provide informed consent for self
Exclusion Criteria:
- Patients with active malignant tumors other than GBM
We found this trial at
1
site
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
Click here to add this to my saved trials
